Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer
Source : https://www.lungcancerjournal.info/article/S0169-5002(21)00639-5/fulltext
Small-cell lung cancer (SCLC) is an aggressive disease and is a neuroendocrine tumor of the lung according to the current World Health Organization classification [1]. Platinum-based chemotherapy is a standard...
Conclusions: This study showed the satisfactory tolerability and efficacy of ramucirumab at 10 mg/kg in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage SCLC.
Elucidation of optimal proteinuria management based on the risk of ramucirumab-induced proteinuria - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34976157/
Proteinuria is a dose-limiting adverse effect of ramucirumab treatment, which is an anti-angiogenic agent that targets the human vascular endothelial growth factor. The predictors of proteinuria have not been completely...
Conclusion: The results from the present study indicated that particular attention should be paid to proteinuria at the start of treatment when monitoring proteinuria as an adverse event of ramucirumab treatment.
NCAPG promotes the oncogenesis and progression of non-small cell lung cancer cells through upregulating LGALS1 expression - Molecular Cancer
Source : https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-022-01533-9
Background Numerous common oncogenic driver events have been confirmed in non-small cell lung cancer (NSCLC). Although targeted therapy has revolutionized NSCLC treatment, some patients still do not respond. NCAPG, also...
Conclusions: This study indicates that NCAPG is one of the essential factors for NSCLC oncogenesis and progression, providing a new target for prognosis prediction and treatment of NSCLC.
A Novel Targeted Delivery of Valeric Acid Using Liposomal Nanoparticles in Treatment of Lung Cell Carcinoma
Source : https://www.ingentaconnect.com/content/asp/jbn/2022/00000018/00000001
this page is secure Volume 18, Number 1, January 2022 Access Key Free content Partial Free content New content Open access content Partial Open access content Subscribed content Partial Subscribed...
Conclusion/Relevance: The current study confirmed that, compared with cisplatin and paclitaxel, this novel liposomal nanoparticle-modified valeric acid displayed significant therapeutic effect on NSCLC, with lower cytotoxicity to normal cells. It has therefore further promoted research progress and significance on NSCLC research in the clinical...
Extent of Resection Influences Survival in Early-Stage Lung Cancer with Occult Nodal Disease
Source : https://www.annalsthoracicsurgery.org/article/S0003-4975(22)00189-8/
Minimal literature exists evaluating the impact of the extent of resection on survival in patients with small, early-stage non-small cell lung cancer (NSCLC) found to have occult nodal disease (OND)....
Conclusions: Review of the National Cancer Database suggests that there is no improvement in overall survival in patients undergoing lobectomy versus segmentectomy in carefully selected patients with clinical Stage IA NSCLC harboring occult nodal disease. However, those undergoing wedge resection may have worse overall survival than those...